The International immunosuppression & Transplant Skin Cancer Collaborative (ITSCC) is an organization of physicians, surgeons and scientists from multiple disciplines dedicated to advancing the care and understanding of skin cancer in organ transplant recipients and other immunosuppressed patients
These patients are up to 65 times more likely to develop skin cancer than people without transplants. Skin cancer is the most common cancer affecting solid organ transplant recipients, affecting up to 70 percent of patients within 20 years, and is the result of intense immunosuppressive regimens.
Learn more about becoming an ITSCC member.
ITSCC stands as a testament to the strength derived from the diversity of its members—physicians, surgeons, and scientists hailing from various disciplines and corners of the globe. Our shared dedication to advancing the understanding and care of skin cancer in organ transplant recipients and immunosuppressed patients is rooted in the inclusive collaboration of these diverse perspectives. We recognize the unique challenges faced by this vulnerable population, and our commitment to inclusivity is a cornerstone in addressing the complexities of cutaneous oncology and transplant dermatology.
With a global membership of approximately 200 professionals and a network that spans the Americas, Europe, Australia, and beyond, ITSCC is not only a hub of diverse expertise but also a leading resource in the field. Our commitment to diversity is more than a principle; it is a driving force behind the innovation, inclusivity, and excellence that define our collaborative efforts. By fostering an environment that values and respects the uniqueness of each member, ITSCC aims to create a space where diverse perspectives contribute to groundbreaking research, education, and clinical advancements. In embracing diversity, ITSCC reaffirms its dedication to improving the lives of transplant recipients and immunosuppressed patients on a global scale.
The mission of ITSCC is to support and integrate collaborative research addressing the care of transplant recipients and other immunosuppressed patients with skin cancer.
We aim to educate patients, researchers, and care teams on the dermatological care unique to transplant recipients and other immunosuppressed patients
ITSCC members believe strongly in the educational goals and mission of the organization, and are proud of our organization’s status as a leading resource in education as well as clinical and basic science investigation in the field of cutaneous oncology and transplant dermatology. From its inception, this belief in and support of the organizational mission and value has helped ITSCC grow to approximately 200 members worldwide, plus a larger network of like-minded physicians, researchers, affiliates and others.
ITSCC was founded in 2001 by a group of dermatologic surgeons from several institutions who saw the need to better manage skin cancers in patients who received solid organ transplants. These patients are up to 65 times more likely to develop skin cancer than people without transplants.
A multi-center collaborative research project conducted at the Mayo Clinic focused on metastatic skin cancer in transplant patients revealed that many physicians were facing challenges treating skin cancers in organ transplant recipients.
A collaborative group, under the name North American Transplant Skin Cancer Collaborative, formed around a shared dedication to finding optimal care for the skin and skin cancer of these patients. As membership diversified to include physicians and researchers from Central and South America, Australia, and other regions, the name was changed to ITSCC.
